A patient goes home. The cardiology finally follows.
Somewhere right now, a person is doing dishes with a small disc stuck below their collarbone. They are not in a hospital gown. There are no wires taped down their ribs, no shoebox recorder on a belt clip, no reason to remember the thing is there at all. And yet - beat by beat - six leads of clinical-grade ECG are climbing off their skin, into the phone on the counter, and onward to a technician who will flag anything that misbehaves. That disc is eWave. The company behind it is Wearlinq.
For decades, heart monitoring made you pick: comfortable and half-blind, or accurate and unbearable. Wearlinq's whole thesis is that this was a false choice.
Cardiac monitoring has long run on a quiet compromise. Single-lead patches are pleasant to wear and easy to forget - which is precisely their problem, because one lead sees the heart from one narrow angle and misses the rest. Wired Holter monitors gather richer, multi-angle data, but they are so fiddly and conspicuous that patients peel them off early, and a monitor in a drawer records nothing. Wearlinq's founders looked at that trade and decided the comfortable device should also be the accurate one.
The company traces back to Stanford, where Konrad Morzkowski - a Swedish-trained engineer and Forbes 30 Under 30 honoree - was doing a master's degree and met a cardiologist who spent his days actually reading these squiggles. Albert Rogers, an electrophysiologist, knew exactly what clinicians were missing when a patch gave them a single point of view. Together they set out to shrink a six-lead ECG down to something patients would tolerate for days on end. Founded in 2019, Wearlinq now runs out of San Francisco with a team of roughly 39 people.
What they built is deliberately unglamorous in the best way. eWave is a lightweight monitor that magnetically snaps onto a patent-pending, skin-like adhesive patch. It talks over Bluetooth to the patient's own smartphone - no proprietary base station to lug around - and streams near-real-time data so clinicians receive reports in under 48 hours. It runs 5+ days between charges, and when it needs power it drops into a case that looks a lot like the one your earbuds live in. When the battery dips or a patch needs replacing, it says so. The device is FDA 510(k)-cleared and, by the company's count, has already been worn by more than a thousand patients.
Wearlinq also did something most hardware startups avoid: it bought the reading room. In 2024 the company acquired AMI Cardiac Monitoring, an independent diagnostic testing facility with more than 33 years of experience and certified cardiographic technicians on duty around the clock. Instead of shipping raw waveforms to a third party and hoping for a fast turnaround, Wearlinq now owns the human layer too - the people who translate signals into STAT reports a cardiologist can act on. Device, app, platform, and diagnosis, under one roof.
Investors noticed. In December 2025 the company closed a $14M Series A led by AIX Ventures, with SpringTide, the Berkeley Catalyst Fund and a long roster of others, plus $5M in venture debt - bringing total funding to roughly $26M. The money is aimed at one unfashionable goal: making a genuinely better clinical device that patients are willing to keep on their bodies.